Answers are grounded in this paper and cite their sources.
Strongyloidiasis remains neglected despite its lethal potential in immunocompromised hosts. Recent Taiwanese data reveal a prevalence of 1.9-4.8 % among at-risk cohorts, challenging assumptions that strongyloidiasis is rare in high-income countries (HICs). This commentary highlights three key implications: (i) systematic screening for elderly and immunosuppressed patients, (ii) integration into One Health surveillance frameworks recognizing zoonotic cycles, and (iii) economic evaluations to define cost-effective screening strategies. Addressing this silent infection is urgent amid expanding migration and immunosuppressive therapy use. Ignoring strongyloidiasis risks preventable morbidity, mortality, and rising healthcare costs in ageing HIC populations.
No takes yet. Share an insight, caveat, or question.
Rattanapitoon et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: